This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Sanofi Inc.
Reference
Rosenthal N, et al. Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome. American Journal of Cardiovascular Drugs : 23 Jun 2020. Available from: URL: https://doi.org/10.1007/s40256-020-00419-9
Rights and permissions
About this article
Cite this article
Enoxaparin in acute coronary syndromes: better outcomes, lower cost. PharmacoEcon Outcomes News 857, 12 (2020). https://doi.org/10.1007/s40274-020-6949-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6949-4